Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.19 -0.4%	$1.22	$0.86 ▼ $3.78	$262.93M	0.35	4.40 million shs	4.19 million shs
GANX Gain Therapeutics	$1.83 -7.3%	$1.68	$0.95 ▼ $3.19	$66.33M	0.1	280,506 shs	687,652 shs
SCPH scPharmaceuticals	$5.52 +13.8%	$4.59	$1.94 ▼ $6.28	$294.21M	0.4	479,074 shs	16.77 million shs
SGMT Sagimet Biosciences	$7.07 -0.5%	$8.67	$1.73 ▼ $11.41	$228.78M	3.37	1.09 million shs	355,971 shs

10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	+8.18%	-20.67%	+12.26%	-54.41%
GANX Gain Therapeutics	0.00%	+13.87%	+16.57%	+9.44%	+52.71%
SCPH scPharmaceuticals	0.00%	+5.43%	-13.39%	+46.53%	-9.68%
SGMT Sagimet Biosciences	0.00%	-7.30%	-30.57%	+106.09%	+141.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	2.6348 of 5 stars	3.4	3.0	0.0	1.6	2.5	0.6
GANX Gain Therapeutics	2.3761 of 5 stars	3.5	3.0	0.0	2.8	0.0	0.6
SCPH scPharmaceuticals	4.5245 of 5 stars	3.3	5.0	4.2	3.2	1.7	0.6
SGMT Sagimet Biosciences	2.826 of 5 stars	3.5	4.0	0.0	1.3	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.75	Moderate Buy	$8.44	612.61% Upside
GANX Gain Therapeutics	3.00	Buy	$7.80	327.16% Upside
SCPH scPharmaceuticals	2.67	Moderate Buy	$14.00	153.58% Upside
SGMT Sagimet Biosciences	3.00	Buy	$25.67	262.88% Upside

Current Analyst Ratings Breakdown

Latest GANX, SCPH, ALLO, and SGMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2025	SCPH scPharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
8/13/2025	GANX Gain Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $6.00
8/11/2025	SGMT Sagimet Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$28.00
8/7/2025	SGMT Sagimet Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$29.00
8/4/2025	ALLO Allogene Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/4/2025	ALLO Allogene Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
7/24/2025	SGMT Sagimet Biosciences	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$28.00
7/3/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/6/2025	SGMT Sagimet Biosciences	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $27.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	13,146.39	N/A	N/A	$2.01 per share	0.59
GANX Gain Therapeutics	$50K	1,312.89	N/A	N/A	$0.28 per share	6.52
SCPH scPharmaceuticals	$49.97M	5.89	N/A	N/A	$0.27 per share	20.45
SGMT Sagimet Biosciences	$2M	115.01	N/A	N/A	$5.08 per share	1.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.11	N/A	N/A	N/A	N/A	-55.99%	-42.75%	11/6/2025 (Estimated)
GANX Gain Therapeutics	-$20.41M	-$0.63	N/A	N/A	N/A	N/A	-289.10%	-155.11%	11/13/2025 (Estimated)
SCPH scPharmaceuticals	-$85.15M	-$1.81	N/A	N/A	N/A	-183.55%	-1,647.86%	-71.76%	11/12/2025 (Estimated)
SGMT Sagimet Biosciences	-$45.57M	-$1.83	N/A	N/A	N/A	N/A	-39.88%	-38.40%	11/13/2025 (Estimated)

Latest GANX, SCPH, ALLO, and SGMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ALLO Allogene Therapeutics	-$0.28	-$0.23	+$0.05	-$0.23	N/A	N/A
8/13/2025	Q2 2025	SGMT Sagimet Biosciences	-$0.52	-$0.32	+$0.20	-$0.32	N/A	N/A
8/12/2025	Q2 2025	GANX Gain Therapeutics	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A
8/7/2025	Q2 2025	SCPH scPharmaceuticals	-$0.30	-$0.34	-$0.04	-$0.34	$15.41 million	$16.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
SCPH scPharmaceuticals	N/A	N/A	N/A	N/A	N/A
SGMT Sagimet Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	8.92	8.92
GANX Gain Therapeutics	0.09	1.79	1.79
SCPH scPharmaceuticals	3.86	3.85	3.14
SGMT Sagimet Biosciences	N/A	17.55	17.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
GANX Gain Therapeutics	11.97%
SCPH scPharmaceuticals	89.52%
SGMT Sagimet Biosciences	87.86%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
GANX Gain Therapeutics	7.18%
SCPH scPharmaceuticals	4.78%
SGMT Sagimet Biosciences	14.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	221.88 million	192.59 million	Optionable
GANX Gain Therapeutics	20	35.95 million	33.37 million	Optionable
SCPH scPharmaceuticals	30	53.30 million	50.75 million	Optionable
SGMT Sagimet Biosciences	8	32.52 million	27.74 million	Optionable

GANX, SCPH, ALLO, and SGMT Headlines

Recent News About These Companies

Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives $25.67 Consensus Target Price from Brokerages

August 23 at 2:35 AM | americanbankingnews.com

Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Buy" by Brokerages

August 21, 2025 | marketbeat.com

Sagimet Biosciences Inc. (SGMT) Upgraded to Buy: What Does It Mean for the Stock?

August 20, 2025 | zacks.com

After Plunging 28% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)

August 20, 2025 | zacks.com

What is Wedbush's Estimate for SGMT Q2 Earnings?

August 16, 2025 | marketbeat.com

Q2 Earnings Estimate for SGMT Issued By Wedbush

August 16, 2025 | americanbankingnews.com

Sagimet Biosciences Enters New Sales Agreement with Leerink

August 15, 2025 | msn.com

Sagimet Biosciences Inc.: Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 13, 2025 | finanznachrichten.de

Sagimet Biosciences Tops Q2 EPS Forecast

August 13, 2025 | aol.comA

Sagimet Biosciences Reports Positive Phase 3 Results for Denifanstat in Acne and Initiates Phase 1 Trials for FASN Inhibitors

August 13, 2025 | quiverquant.comQ

Sagimet Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 13, 2025 | globenewswire.com

Wedbush Initiates Coverage of Sagimet Biosciences (SGMT) with Outperform Recommendation

August 12, 2025 | msn.com

Wedbush Begins Coverage on Sagimet Biosciences (NASDAQ:SGMT)

August 12, 2025 | marketbeat.com

Sagimet Biosciences initiated with an Outperform at Wedbush

August 11, 2025 | msn.com

What is HC Wainwright's Estimate for SGMT Q2 Earnings?

August 11, 2025 | marketbeat.com

Sagimet Biosciences' (SGMT) "Buy" Rating Reaffirmed at HC Wainwright

August 8, 2025 | marketbeat.com

Sagimet Biosciences (SGMT) Projected to Post Earnings on Wednesday

August 6, 2025 | marketbeat.com

Sagimet Biosciences Inc. to Participate in Canaccord Genuity 45th Annual Growth Conference on August 13, 2025

August 5, 2025 | quiverquant.comQ

Sagimet Biosciences to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 5, 2025 | globenewswire.com

Sagimet Biosciences Inc. (NASDAQ:SGMT) Given Average Recommendation of "Buy" by Analysts

July 26, 2025 | marketbeat.com

Sagimet Biosciences (NASDAQ:SGMT) Coverage Initiated at Canaccord Genuity Group

July 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GANX, SCPH, ALLO, and SGMT Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.18 -0.01 (-0.42%)

As of 03:47 PM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Gain Therapeutics NASDAQ:GANX

$1.83 -0.14 (-7.31%)

As of 03:48 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

scPharmaceuticals NASDAQ:SCPH

$5.52 +0.67 (+13.84%)

As of 03:48 PM Eastern

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Sagimet Biosciences NASDAQ:SGMT

$7.07 -0.04 (-0.52%)

As of 03:48 PM Eastern

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time